TOKYO, February 16, 2021 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that it obtained approval from the Ministry of Health, Labour and Welfare (MHLW) for the use of FoundationOne® CDx Cancer Genomic Profile as a companion diagnostic (CDx) for the fibroblast growth factor receptor (FGFR) inhibitor pemigatinib, for patients with FGFR2 fusion positive locally advanced or metastatic biliary tract cancer on February 15, 2021.
“We are very pleased that FoundationOne CDx Cancer Genomic Profile has been approved as a companion diagnostic for pemigatinib in patients with biliary tract cancer. The expanded use of FoundationOne CDx Cancer Genomic Profile for this new cancer type with high unmet medical needs underscores the value of comprehensive genomic profiling in cancer treatment,” said Dr. Osamu Okuda, Chugai’s President and COO. “We are committed to preparing for the use of the genomic profiling to identify those who may benefit from pemigatinib.”
The approval allows the use of FoundationOne CDx Cancer Genomic Profile as a companion diagnostic to identify patients with FGFR2 fusion positive locally advanced or metastatic biliary tract cancer who could benefit from treatment with pemigatinib. Incyte Biosciences Japan submitted a Japanese New Drug Application for pemigatinib for the treatment of FGFR2 fusion positive locally advanced or metastatic cholangiocarcinoma with the MHLW on September 14, 2020 which is currently under review. The MHLW granted orphan drug designation to pemigatinib for this indication.
As a leading company in the field of oncology, Chugai is committed to realizing advanced personalized oncology care and contributing to patients and healthcare professionals through improving access to comprehensive genomic profiling of cancers.
Approval information The underlined part has been newly added.
Intended uses or indications
- The Product is used for comprehensive genomic profiling of tumor tissues in patients with solid cancers.
- The Product is used for detecting gene mutations and other alterations to support the assessment of drug indications listed in the table below.
|Alterations||Cancer type||Relevant drugs|
|Activated EGFR alterations||Non-small cell lung cancer (NSCLC)||afatinib dimaleate, erlotinib hydrochloride, gefitinib, osimertinib mesylate|
|EGFR exon 20 T790M alterations||osimertinib mesylate|
|ALK fusion genes||alectinib hydrochloride, crizotinib, ceritinib|
|ROS1 fusion genes||entrectinib|
|MET exon 14 skipping alterations||capmatinib hydrochloride hydrate|
|BRAF V600E and V600K alterations||Malignant melanoma||dabrafenib mesylate, trametinib dimethyl sulfoxide, vemurafenib|
|ERBB2 copy number alterations (HER2 gene amplification positive)||Breast cancer||trastuzumab (genetical recombination)|
|KRAS/NRAS wild-type||Colorectal cancer||cetuximab (genetical recombination), panitumumab (genetical recombination)|
|NTRK1/2/3 fusion gene||Solid tumors||entrectinib, larotrectinib sulfate|
|BRCA1/2 alterations||Ovarian cancer||olaparib|
|BRCA1/2 alterations||Prostate cancer||olaparib|
|FGFR2 fusion genes||Biliary tract cancer||pemigatinib|
About FoundationOne CDx Cancer Genomic Profile
Developed by Foundation Medicine Inc., FoundationOne CDx Cancer Genomic Profile is a next-generation sequencing based in vitro diagnostic device for the detection of substitutions, insertion and deletion alterations, and copy number alterations in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. The program is available as a companion diagnostic for multiple molecular-targeted drugs approved in Japan.
About fibroblast growth factor receptors
Fibroblast growth factor receptors (FGFRs) play an important role in tumor cell proliferation and survival, migration and angiogenesis (the formation of new blood vessels). Activating mutations, translocations and gene amplifications in FGFRs are closely correlated with the development of various cancers.
Trademarks used or mentioned in this release are protected by laws.
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Tomoko Shimizu
- Tel: +81-3-3273-0881
- E-mail: email@example.com
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: firstname.lastname@example.org